Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: M. Ramle who wrote (2014)	3/17/1999 10:36:00 AM
From: Don Miller	Read Replies (2) \| Respond to of 10280

I went looking for LLY information on SI and found the following report, that is about 45 days old now. Two things jump out of it for me, 1) LLY seems to think they have a run with Prozac until 2004, 2) SEPR is not even mentioned in their alternative plans except possibly in a reference to "New applications of Prozac such as a patented once-a-week formulation and combinations with other drugs and the launch of new molecules to treat depression." The report was as follows: 01/29 08:33 INTERVIEW-Lilly<LLY.N>plans for life after Prozac By Marcel Michelson PARIS, Jan 29 (Reuters) - Eli Lilly and Co., the world's number eight drugs company in market value, is gearing up for life after the 2003 patent expiry of its Prozac blockbuster but is unlikely to seek a major merger with another pharma group. Sidney Taurel, the chairman, president and chief executive, said Lilly looked to new products to make up the loss of its Prozac monopoly. Many recent mergers in the industry had not created long-term shareholder value, he told Reuters in an interview. One product planned for launch in 2002 is a challenger to Pfizer's <PFE.N> Viagra developed in a joint venture with ICOS Corp <ICOS.O>. "It is still in the early stages but it looks like it may work as well as Viagra but without having some of the problems of Viagra, (such as) headaches and cardiovascular problems," Taurel said. Eli Lilly, named after its founder who created the firm in 1876, on Thursday reported a 24 percent rise in 1998 net income to $567.3 million. On Monday, it settled a patents challenge to its Prozac drug which makes up 28 percent of sales. Its profits contribution was higher but Taurel did not specify. Taurel said it was now unlikely there would be generic versions of Prozac until 2004: "We won a big battle." Barr Laboratories Inc <BRL.N> and Novartis AG <NOVZn.S> unit Geneva Pharmaceuticals Inc are appealing a judge's decision to dismiss their challenge to Lilly's "composition of matter" patent on Prozac which expires in February 2001. This appeal procedure is expected to take some 12 to 18 months. A challenge to the "mode of action" patent on Prozac, expiring in December 2003, is not expected to start until the first appeal is finished. The second challenge is by Teva <TEVI.TA> of Israel, Zenith-Goldline and Reddy <REDY.BO> of India. Taurel said the Prozac patent could be extended by another six months as it features on a special list of drugs backed by the U.S. Food and Drugs Administration regulator. "We won't see generics until 2004 and by then our dependance on Prozac will be reduced," he said. Lilly has a three-pronged strategy for life after 2003. * New applications of Prozac such as a patented once-a-week formulation and combinations with other drugs and the launch of new molecules to treat depression. * Put more research and development money on promising molecules to accelerate their market launch, with among the most promising ones a treatment for hyperactivity disorder, diabetes and versions of Evista for cancer treatment. * More licencing deals such as the partnership with Takeda Chemical Industries <4502.T> of Japan on a diabetes drug. Taurel saw no need for Lilly to participate in the recent spate of drugs mega-mergers. "We want to continue alone but supplemented by partnerships, acquisitions of molecules and technologies, and potential targeted acquisitions to increase our marketing and distribution capacity in areas outside of the United States where we are less strong, like in Japan," Taurel said. The company was also weak in Germany and Italy, he said.